<DOC>
	<DOCNO>NCT02825940</DOCNO>
	<brief_summary>This phase I , open-label , multicenter study evaluate pharmacokinetics , safety , preliminary anti-tumor activity atezolizumab Chinese participant locally advance metastatic gastric cancer , nasopharyngeal cancer , esophageal cancer , hepatocellular carcinoma ( HCC ) , solid tumor type refractory standard therapeutic modality standard therapy available refused standard therapy .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics Safety Atezolizumab Administered Intravenously Chinese Participants With Locally Advanced Metastatic Solid Tumors ( IMYO29233 )</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically document , incurable metastatic solid tumor advance ( nonresectable ) recurrent progress since last antitumor therapy recognize standard curative therapy exist refuse standard therapy Adequate hematologic end organ function Measurable disease per Response Evaluation Criteria Solid Tumors Version 1.1 ( RECIST v1.1 ) modify Response Evaluation Criteria Solid Tumors ( mRECIST ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Women postmenopausal ( great equal [ &gt; /= ] 12 month nontherapyinduced amenorrhea ) surgically sterile must negative serum pregnancy test result within 14 day prior initiation study treatment Women childbearing potential must agree remain abstinent use contraceptive method specify study For enrollment China extension cohort , residence People 's Republic China Any approve anticancer therapy , include chemotherapy , target therapy hormonal therapy le ( &lt; ) 5 halflives prior initiation study treatment Treatment investigational agent participation another clinical trial therapeutic intent within 28 day prior enrollment Uncontrolled hypercalcemia ( great [ &gt; ] 1.5 millimol per liter [ mmol/L ] ionize calcium calcium &gt; 12 milligram per deciliter ( mg/dL ) correct serum calcium great upper limit normal [ ULN ] ) symptomatic hypercalcemia require continue use bisphosphonate therapy Known clinically significant liver disease , include active viral , alcoholic , hepatitis , cirrhosis , fatty liver , inherit liver disease Participants acute leukemia , accelerated/blastphase chronic myelogenous leukemia , chronic lymphocytic leukemia , Burkitt lymphoma , plasma cell leukemia , nonsecretory myeloma Active untreated central nervous system ( CNS ) metastasis determine computed tomography magnetic resonance image evaluation screen prior radiographic assessment Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication History human immunodeficiency virus , hepatitis B ( except HCC cohort ) , hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>